Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease
© 2023. The Author(s)..
COVID-19 is often associated with long-lasting pulmonary symptoms. Data are scarce about interstitial lung disease (ILD) in patients following COVID-19 hospitalization with persistent symptoms. We retrospectively reviewed all cases sent to pulmonary post-COVID evaluation due to persistent symptoms between February 2021 and February 2022 (N = 318). All patients with suspected ILD (N = 44) were reviewed at the multidisciplinary discussion. Patient characteristics, symptoms, time since hospitalization, detailed lung function measurements and 6-min walk test (6MWT) were evaluated. The post-COVID ILD suspected group included more men (68.2 vs. 31.8%) with significantly older age compared to the control group (64.0 ± 12.3 vs. 51.3 ± 14.9 years). Most patient needed hospital care for COVID-19 pneumonia (68.6% of all patients and 84.1% of ILD suspected group) and average time since hospitalization was 2.4 ± 2.3 months. Persisting symptoms included fatigue (34%), dyspnoea (25.2%), cough (22.6%), and sleep disorders (insomnia 13.2%; sleepiness 8.2%). Post-COVID ILD presented more often with new symptoms of cough and sleepiness. Functional impairment, especially decreased walking distance and desaturation during 6-min walk test (6MWT) were detected in the ILD-suspected group. Respiratory function test in the post-COVID ILD group showed slight restrictive ventilatory pattern (FVC: 76.7 ± 18.1%, FEV1: 83.5 ± 19.1%, TLC: 85.6 ± 28.1%) and desaturation during 6MWT were detected in 41% of patients. LDCT changes were mainly ground glass opacities (GGO) and/or reticular abnormalities in most cases affecting < 10% of the lungs. Our data indicate that suspected post-COVID ILD is affecting 13.8% of symptomatic patients. High resolution chest CT changes were mainly low extent GGO/reticulation, while long-term lung structural changes need further evaluation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
---|---|
Enthalten in: |
Inflammopharmacology - 31(2023), 2 vom: 24. Apr., Seite 565-571 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Fesu, Dorottya [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 pneumonia |
---|
Anmerkungen: |
Date Completed 01.05.2023 Date Revised 24.05.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10787-023-01191-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354668021 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM354668021 | ||
003 | DE-627 | ||
005 | 20231226062718.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10787-023-01191-3 |2 doi | |
028 | 5 | 2 | |a pubmed24n1182.xml |
035 | |a (DE-627)NLM354668021 | ||
035 | |a (NLM)36961666 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Fesu, Dorottya |e verfasserin |4 aut | |
245 | 1 | 0 | |a Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.05.2023 | ||
500 | |a Date Revised 24.05.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a COVID-19 is often associated with long-lasting pulmonary symptoms. Data are scarce about interstitial lung disease (ILD) in patients following COVID-19 hospitalization with persistent symptoms. We retrospectively reviewed all cases sent to pulmonary post-COVID evaluation due to persistent symptoms between February 2021 and February 2022 (N = 318). All patients with suspected ILD (N = 44) were reviewed at the multidisciplinary discussion. Patient characteristics, symptoms, time since hospitalization, detailed lung function measurements and 6-min walk test (6MWT) were evaluated. The post-COVID ILD suspected group included more men (68.2 vs. 31.8%) with significantly older age compared to the control group (64.0 ± 12.3 vs. 51.3 ± 14.9 years). Most patient needed hospital care for COVID-19 pneumonia (68.6% of all patients and 84.1% of ILD suspected group) and average time since hospitalization was 2.4 ± 2.3 months. Persisting symptoms included fatigue (34%), dyspnoea (25.2%), cough (22.6%), and sleep disorders (insomnia 13.2%; sleepiness 8.2%). Post-COVID ILD presented more often with new symptoms of cough and sleepiness. Functional impairment, especially decreased walking distance and desaturation during 6-min walk test (6MWT) were detected in the ILD-suspected group. Respiratory function test in the post-COVID ILD group showed slight restrictive ventilatory pattern (FVC: 76.7 ± 18.1%, FEV1: 83.5 ± 19.1%, TLC: 85.6 ± 28.1%) and desaturation during 6MWT were detected in 41% of patients. LDCT changes were mainly ground glass opacities (GGO) and/or reticular abnormalities in most cases affecting < 10% of the lungs. Our data indicate that suspected post-COVID ILD is affecting 13.8% of symptomatic patients. High resolution chest CT changes were mainly low extent GGO/reticulation, while long-term lung structural changes need further evaluation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 pneumonia | |
650 | 4 | |a High resolution CT | |
650 | 4 | |a Interstitial lung disease | |
650 | 4 | |a Lung function | |
650 | 4 | |a Post-COVID-19 | |
650 | 4 | |a Respiratory symptoms | |
700 | 1 | |a Polivka, Lorinc |e verfasserin |4 aut | |
700 | 1 | |a Barczi, Eniko |e verfasserin |4 aut | |
700 | 1 | |a Foldesi, Marcell |e verfasserin |4 aut | |
700 | 1 | |a Horvath, Gabor |e verfasserin |4 aut | |
700 | 1 | |a Hidvegi, Edit |e verfasserin |4 aut | |
700 | 1 | |a Bohacs, Aniko |e verfasserin |4 aut | |
700 | 1 | |a Muller, Veronika |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 31(2023), 2 vom: 24. Apr., Seite 565-571 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2023 |g number:2 |g day:24 |g month:04 |g pages:565-571 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-023-01191-3 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 31 |j 2023 |e 2 |b 24 |c 04 |h 565-571 |